Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emrusolmin
- Development stage
- Phase 2
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Emrusolmin (TEV-56286, Anle138b) is an investigational small molecule drug being developed by Teva Pharmaceutical Industries and MODAG GmbH for the treatment of Multiple System Atrophy (MSA). It functions as an oligomer modulator and aggregation inhibitor that specifically targets pathological alpha-synuclein oligomers, which are toxic protein assemblies believed to be central to the pathogenesis of synucleinopathies. By binding to and modulating these oligomers, emrusolmin aims to prevent the formation of larger aggregates and reduce neurotoxicity. The drug is administered orally in capsule form and is currently in Phase 2 clinical development, notably in the TOPAS-MSA trial. It has received FDA Fast Track and Orphan Drug designations for the treatment of MSA.
- Brand names
- Emrusolmin
- Other names
- 882697-00-9Emrusolmin [INN]3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1h-pyrazoleE7WRA77JETE-7WRA77JETE 7WRA77JETCHEMBL4748063CHEMBL-4748063CHEMBL 4748063BCP32558BCP-32558BCP 32558NSC805132NSC-805132NSC 805132
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))Amyloid-beta aggregate (N-terminal epitope)PrPSc (Major prion protein)
Beyond the preview
Go deeper on emrusolmin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emrusolmin.